Whipplewood Advisors LLC Cuts Position in Novo Nordisk A/S $NVO

Whipplewood Advisors LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 23.5% during the second quarter, HoldingsChannel reports. The institutional investor owned 4,257 shares of the company’s stock after selling 1,310 shares during the quarter. Whipplewood Advisors LLC’s holdings in Novo Nordisk A/S were worth $294,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NVO. Revolve Wealth Partners LLC lifted its position in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Novo Nordisk A/S by 9.6% in the 1st quarter. GAMMA Investing LLC now owns 9,466 shares of the company’s stock worth $657,000 after buying an additional 827 shares in the last quarter. Spire Wealth Management boosted its position in Novo Nordisk A/S by 8.2% in the 1st quarter. Spire Wealth Management now owns 12,862 shares of the company’s stock valued at $893,000 after buying an additional 978 shares during the last quarter. Golden State Wealth Management LLC grew its stake in shares of Novo Nordisk A/S by 127.1% during the first quarter. Golden State Wealth Management LLC now owns 4,128 shares of the company’s stock valued at $287,000 after acquiring an additional 2,310 shares in the last quarter. Finally, Park Place Capital Corp lifted its stake in shares of Novo Nordisk A/S by 26.1% in the first quarter. Park Place Capital Corp now owns 1,683 shares of the company’s stock worth $117,000 after acquiring an additional 348 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 0.4%

Shares of NVO stock opened at $53.02 on Friday. The firm has a market capitalization of $236.74 billion, a PE ratio of 14.57, a price-to-earnings-growth ratio of 2.41 and a beta of 0.68. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $114.19. The stock has a fifty day moving average of $56.56 and a two-hundred day moving average of $62.40.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.69 billion for the quarter, compared to analysts’ expectations of $77.51 billion. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s payout ratio is presently 22.53%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. BNP Paribas upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 13th. Dbs Bank raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. Hsbc Global Res upgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 1st. Rothschild & Co Redburn upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. Finally, UBS Group lowered shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $76.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.